SEC Form 4 · accession 0000310158-26-000219
Merck & Co., Inc. · MRK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard R. DeLuca
Officer — EVP&Pres, Merck Animal Heallth
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000310158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 10, 2026 | S | 20,784 | $130.4345 | D | 134,703 | D | |
| Common StockF2 | Aug 11, 2026 | S | 7,410 | $131.3313 | D | 127,293 | D | |
| Common StockF3 | Aug 11, 2026 | S | 5,427 | $132.3496 | D | 121,866 | D | |
| Common StockF4 | Aug 12, 2026 | S | 11,099 | $131.6128 | D | 110,767 | D | |
| Common StockF5 | Aug 12, 2026 | S | 600 | $132.0367 | D | 110,167 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.6514, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.